Navigation Links
Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting
Date:12/6/2007

cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to progress and timing of clinical trials for Specifid, including difficulties or delays in development, testing, manufacturing and marketing Specifid or Favrille's other product candidates; delays in the availability of data from Favrille's Phase 3 clinical trial; Favrille's ability to obtain marketing approval for Specifid or Favrille's other product candidates and the timing of any such approvals, including whether it will receive expedited review as a result of the Fast Track designation; Favrille's ability to demonstrate that its idiotype protein produced from insect cell lines may stimulate a more effective immune response compared to idiotype protein derived from mammalian cells; Favrille's ability to manufacture sufficient quantities of Specifid for use in clinical trials and, if Specifid receives marketing approval, for commercialization; risks associated with achieving projected operating metrics and financial performance or the anticipated number of patients using Specifid; potential delays in patient enrollment; Favrille's ability to obtain additional financing to support its operations; and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. In addition, conclusions regarding the safety and efficacy of Favrille's product candidates cannot be made until the results of future clinical trials of longer duration in more patients are known. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward- looking statements contained in this release as a result of new information, future events or o
'/>"/>
SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Virginia Tech Report Has National Importance
2. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
3. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
4. Haemacure Reports Third Quarter 2007 Results
5. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
6. Biotech Finishes on a High in August, Burrill Report Says
7. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
8. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
9. MDS Reports Third Quarter 2007 Results
10. First New York/New Jersey Health Care Report Card Released
11. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... The emergence of nanotechnology has ... past decade. The pharmaceutical world has witnessed advancements ... the form of liposomes and polymeric nanoparticles that ... safety and efficiency. In the area of ... upon the enhanced permeability and retention (EPR) effect ...
(Date:3/4/2015)... (PRWEB) March 05, 2015 The ... a value of $5,632.8 million by 2019, at ... of 2014 to 2019. , Browse through the ... analysis of industry trends and segments, with the ... , Phthalic Anhydride (PA) is a derivative ...
(Date:3/4/2015)... March 04, 2015 Dr. Christopher Asandra, ... Medical Center today lamented the FDA’s recent decision ... (TRT). He argued that FDA’s conclusions are not ... men who suffer from testosterone deficiency. , “The FDA ... on testosterone replacement therapy,” said Dr. Asandra. “There is ...
(Date:3/4/2015)... March 04, 2015 FDA’s New Inspection ... **FDAnews Webinar**, March 24, 2015 — 1:30 p.m. – ... generally know within four hours of an inspection whether ... is on their “good” list, they’ll merely ask for ... manufacturer is on the “bad” list, the manufacturer must ...
(Date:3/4/2015)... York, NY (PRWEB) March 04, 2015 ... creative, breakthrough marketing campaign called 'We Love Smokers' from ... cravings for tobacco. , "It’s important to establish ... be true to it. Our idea, 'We Love Smokers' ... leadership point of view. We created a bold tone ...
Breaking Medicine News(10 mins):Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 2Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 3Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 2Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 3Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 2Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 3
... to Iowa from Los Angeles; more ... shipments from Chicago planned, LOS ANGELES, ... Christian relief agency World Vision is dispatching an,initial truckload of emergency ... of affected families., "World Vision will be providing basic items ...
... complain that math homework won,t help them in real life, ... cancer. , In a recent study that combined math and ... (CML) may be cured of the disease with an optimally ... their own immune response. , In the June 20 edition ...
... to pulmonary arterial hypertension, study found , , THURSDAY, ... reduced clinical decline in patients with early-stage pulmonary ... is a progressive disease in which increased pulmonary ... the heart, eventually leading to heart failure and ...
... Pa., June 19 ADVERTISEMENT - The following,statement was ... Topaz &,Kessler, LLP:, Schiffrin Barroway Topaz & Kessler, ... In re Merck & Co. Inc. Securities, Derivative, &,ERISA ... Court for the,District of New Jersey. The Court recently ...
... Fix Competitive Bidding System for DMEPOS,Equipment, ALEXANDRIA, ... of the House Ways & Means Health Subcommittee, ... Reform,Act of 2008. Sens. Max Baucus (D-MT) and ... Senate Finance Committee, have introduced S.3144, the,companion bill. ...
... to Pennsylvania-Grown Tomatoes, HARRISBURG, Pa., June 19 ... been confirmed among Pennsylvania,residents, State Health Secretary Dr. ... to the current multi-state Salmonella outbreak,associated with tomatoes ... April., One case each has been identified ...
Cached Medicine News:Health News:World Vision Responding to Record Flooding in Midwest 2Health News:Math could help cure leukemia 2Health News:Math could help cure leukemia 3Health News:Drug Effective Against Heart-Lung Disorder 2Health News:Schiffrin Barroway Topaz & Kessler, LLP Announces Court Ruling Relating to Merck & Co. Inc.'s Employee Savings & Security Plan, the Merck & Co., Inc. Employee Stock Purchase & Savings Plan, and the Merck Puerto Rico Employee Savings & Security Plan 2Health News:Schiffrin Barroway Topaz & Kessler, LLP Announces Court Ruling Relating to Merck & Co. Inc.'s Employee Savings & Security Plan, the Merck & Co., Inc. Employee Stock Purchase & Savings Plan, and the Merck Puerto Rico Employee Savings & Security Plan 3Health News:NCPA Statement Endorsing H.R. 6252 and S.3144 2Health News:Pennsylvania Department of Health Confirms Fifth Salmonella Case Linked to National Outbreak 2
(Date:3/4/2015)... 4, 2015  The strongest driver of demand ... increasing elderly population, according to Kalorama Information. The ... the healthcare market research publisher, Global Orthopedic ... risk factors such as obesity is contributing to ... innovative product designs and the trend toward cost ...
(Date:3/4/2015)... DIEGO , March 4, 2015  Tandem Diabetes Care®, ... and manufacturer of the t:slim® and t:flex™ Insulin Pumps, today ... of 6,037,500 shares of common stock at a price to ... in full by the underwriters of their option to purchase ... in the offering were offered by Tandem. ...
(Date:3/4/2015)... PARK, Calif. , March 4, 2015 ... company in the emerging field of regenerative medicine, today ... Executive Officer, will ring The Opening Bell ® ... March 5, 2015. Asterias began trading as an NYSE ... "New York Stock Exchange is a trusted partner ...
Breaking Medicine Technology:Kalorama: Growing Elderly Population Drives Orthopedic Device Market 2Kalorama: Growing Elderly Population Drives Orthopedic Device Market 3Tandem Diabetes Care Announces Closing of Underwritten Public Offering of Common Stock 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 3
... (OTCQX: DATA), a technology and services company focused on global ... signing of a new client with the award of a ... in aneurysm repair. This six year, US-based study will ... for thoracic aortic aneurysms. , "DATATRAK is excited to work ...
... Healthcare Services, Inc. (NYSE: AHS ), the largest healthcare ... conference call to discuss third quarter results on Thursday, October ... expects to issue an earnings news release on Thursday, October ... p.m. Eastern Time. , A live webcast of the call ...
Cached Medicine Technology:DATATRAK Signs 6 Year Study with New Device Client 2DATATRAK Signs 6 Year Study with New Device Client 3AMN Healthcare Services to Host 2009 Third Quarter Earnings Conference Call on Thursday, October 29, 2009 2
The Buffered Wright Stain is a single solution stain that contains the fixative, buffer, and stain for rapid and convenient staining of blood smears. It is packaged in a 32-oz. bottle for ease of use...
Our Wright stain is a dual-use stain for peripheral blood and bone marrow smears. It produces results similar to those of the Giemsa stain with a slightly greater contrast....
Albumin (BCG). Storage temp: 15 -30 C. Linearity: 0.5 - 6.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 500 number of tests....
For the quantitative determination of Albumin in serum. Endpoint procedure with Amax at 630 nm. Linearity: to 6 g/dl. Liquid ready-to-use reagent....
Medicine Products: